RADICAVA ORS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RADICAVA ORS (RADICAVA ORS).
Radicava ORS (edaravone) is a free radical scavenger that reduces oxidative stress by quenching hydroxyl radicals and other reactive oxygen species, thereby mitigating neuronal damage in amyotrophic lateral sclerosis (ALS).
| Metabolism | Edaravone is primarily metabolized by glucuronidation (via UGT1A1, UGT1A6, UGT1A9, UGT2B7) and sulfation; also undergoes methylation. Minor metabolism via CYP1A2 and CYP2A6. |
| Excretion | Primarily renal excretion (78-86% of dose), with 66-74% as unchanged drug; fecal excretion accounts for approximately 1-2%. |
| Half-life | Terminal elimination half-life is approximately 4-5 hours in healthy adults, with no significant accumulation upon repeated dosing. |
| Protein binding | Approximately 90-92% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.3-1.8 L/kg, indicating extensive distribution into total body water. |
| Bioavailability | Not applicable for oral route; RADICAVA ORS is not commercially available. For intravenous edaravone, bioavailability is 100%. |
| Onset of Action | Edaravone requires intravenous administration; clinical effects on functional decline in ALS are observed after 6 months of continuous treatment. |
| Duration of Action | Clinical benefit is sustained with continued monthly cycles; discontinuation leads to loss of effect, with decline in ALS functional rating scale scores returning to natural progression rate. |
Oral, 60 mg once daily for 14 days, followed by a 14-day drug-free period, repeated in cycles.
| Dosage form | SUSPENSION |
| Renal impairment | No adjustment recommended for mild to moderate renal impairment; not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; monitor for adverse effects as elderly patients may have reduced physiological reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RADICAVA ORS (RADICAVA ORS).
| Breastfeeding | No data on edaravone in human milk; M/P ratio unknown. Excretion in animal milk not reported. Due to unknown effects on nursing infant, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Edaravone (RADICAVA ORS) has limited human data. In animal studies, no teratogenic effects were observed in rats or rabbits at exposures up to 3-5 times the human dose. However, as a free radical scavenger, theoretical risk exists. In first trimester, embryofetal developmental toxicity cannot be excluded; in second and third trimesters, no specific risks identified but use only if benefit outweighs risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["History of hypersensitivity to edaravone or any ingredient in the formulation.","Patients with sulfite allergy."]
| Precautions | ["Hypersensitivity reactions (including anaphylaxis) may occur; discontinue if severe.","Sulfite allergy: Contains sodium bisulfite, which may cause allergic reactions in susceptible individuals.","Pregnancy: Use only if benefit outweighs risk; limited human data.","Renal impairment: Not recommended in severe renal impairment (CrCl <30 mL/min)."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal hematology (complete blood count) and renal function (serum creatinine) periodically. No specific fetal monitoring required; standard obstetric care. |
| Fertility Effects | In animal studies, edaravone did not impair fertility in male or female rats. Human data are lacking; no adverse effects on fertility reported. |